1 GOLD. Global strategy for the diagnosis, management and prevention of COPD, global initiative for chronic obstructive lung disease (GOLD);2019. [Update 2019] Available from: http://goldcopd.org. Accessed February 5, 2019
2 Adeloye D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E, et al. Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Glob Health 2015; 5:020415.doi: 10.7189/jogh.05-020415
3 Projections of mortality and causes of death, 2015 and 2030. Geneva: World Health Organization; Available from: http://www.who.int/healthinfo/global_burden_disease/projections/en/ (Accessed on September 11, 2017).
4 Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J Suppl. 2003;41:46s–53s.
5 Rubinsztajn R, Przybylowski T, Maskey-Warzechowska M, Karwat K, Chazan R. Exacerbations of chronic obstructive pulmonary disease and quality of life of patients. Adv Exp Med Biol. 2016;884:69–74.
6 Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847–852.
7 Schmidt SAJ, Johansen MB, Olsen M, Xu X, Parker JM, Molfino NA, Lash TL, Sørensen HT, Christiansen CF. The impact of exacerbation frequency on mortality following acute exacerbations of COPD: a registry-based cohort study. BMJ Open. 2014;4:e006720.
8 Rhee C K , Kim D K . Role of phosphodiesterase-4 inhibitors in chronic obstructive pulmonary disease[J]. Korean J Intern Med, 2020, 35(2):276-283.
9 Agusti A G N , Noguera A , Sauleda J , et al. Systemic effects of chronic obstructive pulmonary disease[J]. Eur Respir J, 2003, 21(2):347-360.
10 Jing Z , Chun C , Ning S , et al. Systemic Inflammatory Marker CRP Was Better Predictor of Readmission for AECOPD Than Sputum Inflammatory Markers[J]. Arch Bronconeumol (English Edition), 2016.
11 Gao J , Chen B , Wu S , et al. Blood cell for the differentiation of airway inflammatory phenotypes in COPD exacerbations[J]. BMC Pulm Med, 2020, 20.
12 Angela, M, Abbatecola, et al. Practical management problems of chronic obstructive pulmonary disease in the elderly: acute exacerbations.[J]. Curr Opin Pulm Med, 2011.
13 Fernandez-Villar A, Soriano JB, Lopez-Campos JL. Overdiagnosis of COPD: precise definitions and proposals for improvement. Br J Gen Pract. 2017;67:183–4.
14 Hartl S, Lopez-Campos JL, Pozo-Rodriguez F, Castro-Acosta A, Studnicka M, Kaiser B, et al. Risk of death and readmission of hospital-admitted COPD exacerbations: European COPD Audit. Eur Respir J. 2016;47:113–21.
15 Wu H, Wise RA, Medinger AE. Do Patients Hospitalized With COPD Have Airflow Obstruction? Chest. 2017;151:1263–71.
16 Ulmer WT. Lung function--clinical importance, problems, and new results.[J]. J PHYSIOL PHARMACOL, 2003, 54 Suppl 1(2):11.
17 Vapnik V N. The nature of statistical learning theory [M]. New York: Springer, 2000: 138-167.
18 GLI-2012 desktop software for individual calculations. http://www.ers-education.org/guidelines/global-lung-function-initiative/spirometry-tools/desktop-individual-calculator.aspx. Last access Jun 3rd 2018.
19 Donner C F , Carone M , Bertolotti G , et al. Methods of assessment of quality of life[J]. Eur Respir Rev, 1997, 7(42):43-45.
20 Manhire A , Charig M , Clelland C , et al. Guidelines for radiologically guided lung biopsy[J]. Thorax, 2003, 58(11):920-36.
21 Berge M V D , Hop W C , Molen T V D , et al. Prediction and course of symptoms and lung function around an exacerbation in chronic obstructive pulmonary disease[J]. Respir Res, 2012, 13(1):44.
22 Celli BR, Thomas NE, Anderson JA, et al. Effect of Pharmacotherapy on Rate of Decline of Lung Function in Chronic Obstructive Pulmonary Disease [J]. Am J Respir Crit Care Med, 2008, 178(4):332-338.
23 Torun E , Cakir E , Özgüç, Fatma, et al. The Effect of Obesity Degree on Childhood Pulmonary Function Tests[J]. Balkan Med J, 2014, 31(3):235-238.
24 Jing C,Yang Z, Qun Y et al. Prediction models for pulmonary function during acute exacerbation of chronic obstructive pulmonary disease [J]. Physiol Meas, 2020, 41, 125010.
25 Lonergan, M., Dicker, A.J., Crichton, M.L. et al. Blood neutrophil counts are associated with exacerbation frequency and mortality in COPD[J]. Respir Res, 2020, 21: 166.
26 Milara J, Juan G, Peiro T, Serrano A, Cortijo J. Neutrophil activation in severe, early-onset COPD patients versus healthy non-smoker subjects in vitro: effects of antioxidant therapy. Respiration. 2012;83(2):147–58.
27 Jones AW, Robinson R, Mohamed P, Davison G, Izzat HJ, Lewis KE. Impaired blood neutrophil function in the frequent Exacerbator of chronic obstructive pulmonary disease: a proof-of-concept study. Lung. 2016;194(6):881–7.
28 Corhay J , Moermans C , Henket M , et al. Increased of exhaled breath condensate neutrophil chemotaxis in acute exacerbation of COPD[J]. Respir Res, 2014, 15(1):115.
29 Perera WR, Hurst JR, Wilkinson TM, et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J. 2007;29(3):527–34.
30 Vapnik V N. The nature of statistical learning theory [M]. New York: Springer, 2000: 138-167.
31 Cristóbal, Esteban, Inmaculada, et al. A decision tree to assess short-term mortality after an emergency department visit for an exacerbation of COPD: a cohort study[J]. Respir Res, 2015.
32 Godtfredsen N S , Jrgensen D V , Marsaa K , et al. Soluble urokinase plasminogen activator receptor predicts mortality in exacerbated COPD[J]. Respir Res, 2018, 19(1):97.